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Abstract
Haemorrhage following injury is associated with 
significant morbidity and mortality. The role of 
fibrinogen concentrate in trauma-induced coagulopathy 
has been the object of intense research in the last 10 
years and has been systematically analysed in this 
review. A systematic search of the literature identified six 
retrospective studies and one prospective one, involving 
1,650 trauma patients. There were no randomised trials. 
Meta-analysis showed that fibrinogen concentrate has 
no effect on overall mortality (risk ratio: 1.07, 95% 
confidence interval: 0.83-1.38). Although the meta-
analytic pooling of the current literature evidence 
suggests no beneficial effect of fibrinogen concentrate in 
the setting of severe trauma, the quality of data retrieved 
was poor and the final results of ongoing randomised 
trials will help to further elucidate the role of fibrinogen 
concentrate in traumatic bleeding. 
Keywords: fibrinogen concentrate, trauma, bleeding, 
mortality.
Introduction
Severe trauma is a major cause of mortality, being 
responsible for more than five million deaths annually 
worldwide1. Uncontrolled post-traumatic bleeding 
is the leading cause of death among these patients 
and is a major challenge for trauma care providers2. 
Blood loss that leads to an endogenous derangement 
of haemostasis, as well as dilutional and consumption 
coagulopathy complicate the control of haemorrhage 
in these patients. It has been estimated that about one 
third of all bleeding trauma patients present with a 
coagulopathy upon admission to hospital3. This early 
trauma-induced coagulopathy, which significantly 
worsens the patients' prognosis4, is nowadays a well-
recognised multifactorial condition resulting from 
a combination of bleeding-induced shock, tissue 
injury-related thrombin-thrombomodulin-complex 
generation and the activation of anticoagulant and 
fibrinolytic pathways5-7. In this context, it is evident that 
the immediate correction of the acquired coagulation 
disorder is one of the primary goals of the treatment 
protocols of trauma centres8. Among the various 
haemostatic treatments available, supplementation of 
fibrinogen has received growing attention in the last 
years9,10, considering that this is the first coagulation 
factor to reach a critically low concentration during 
activation of coagulation and bleeding and its reduction 
is associated with a worse outcome in injured patients11,12. 
Fibrinogen is a plasma glycoprotein synthesised by the 
liver which plays a critical role in haemostasis by acting 
as an endogenous substrate for fibrin formation and by 
inducing clot formation and platelet aggregation13,14. 
Fibrinogen supplementation can be achieved using 
fresh-frozen plasma, cryoprecipitate or plasma-derived, 
virally-inactivated, fibrinogen concentrate15-18, with 
the available therapeutic approaches differing from 
country to country14. Traditionally, a threshold level of 
1.0 g/L was established for fibrinogen supplementation 
in patients with congenital fibrinogen deficiency14, 
whereas the threshold for patients with acquired 
fibrinogen deficiency, including those with trauma-
related coagulopathy, is still debated. In fact, with 
the exception of a few guidelines that indicate trigger 
levels of fibrinogen less than 1.5-2 g/L19-21, the previous 
recommendations, including the Italian Society of 
Transfusion Medicine and Immunohaematology 
(SIMTI, Società Italiana di Medicina Trasfusionale 
e Immunoematologia) guidance document17, indicate 
levels less than 0.8-1 g/L. Current European guidelines 
recommend supplementation of fibrinogen concentrate 
in trauma patients if significant bleeding is accompanied 
by viscoelastic signs of a functional fibrinogen deficit 
or a plasma fibrinogen level of less than 1.5-2.0 g/L 
(grade 1C)1, but this recommendation appears to reflect 
the opinion of the panel of experts rather than being 
based on evidence22,23. Indeed, although a number of 
randomised controlled trials investigating the use of 
fibrinogen concentrate in severe traumatic haemorrhage 
are currently underway, their results have not yet been 
published in full24-26. Moreover, the urgently needed, 
well-conducted, additional prospective clinical trials in 
bleeding patients with acquired fibrinogen deficiency 
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should not only focus on dosing strategies and thresholds 
but should also be adequately powered to detect 
main and secondary selected outcomes27. The aim of 
this review is to analyse systematically the available 
literature evaluating the role of fibrinogen concentrate 
in the management of severe trauma.
Methods
Search methods 
A computer-assisted literature search of the 
MEDLINE, EMBASE and SCOPUS electronic 
databases was performed to identify reports on clinical 
experience of the use of fibrinogen concentrate 
in patients with trauma. We used the search term 
combination "fibrinogen concentrate" and "trauma" or 
"bleeding". In addition, we hand-searched the reference 
lists of the most relevant items (original studies and 
reviews) in order to identify further eligible studies not 
captured in the initial literature search.
Study selection
Studies were selected independently by two 
reviewers (MF and CM), with disagreements resolved 
through discussion and on the basis of the opinion 
of a third reviewer (GML). Assessment of potential 
eligibility was based on the title or abstract and on the 
full text if required. Articles were eligible if they reported 
the fibrinogen concentrate used in the management of 
severe trauma patients. Only studies published in full 
in English between January 2000 and February 2017 
and enrolling at least ten patients were included in 
this systematic review. For each study included in the 
systematic review, the following data were extracted 
by two reviewers (MF and GM) independently: study 
design, sample size, protocol (fibrinogen plasma level 
threshold, comparative group) and results (dose of 
fibrinogen administered, outcomes), adverse events.
Outcomes
According to the study design of the different trials, 
the following outcomes were considered: mortality 
(overall in-hospital mortality, mortality at 6 hours, 
mortality at 24 hours, mortality at 72 hours, mortality at 7 
days, mortality at 30 days and time to death), transfusion 
requirements (red blood cells and platelets), laboratory 
coagulation parameters and clinical outcomes (sepsis, 
multi-organ failure, days of ventilation, duration of 
hospitalisation and thromboembolic events).
Statistical evaluation and meta-analysis
The study designs were reviewed and the quality of 
the evidence at study level was evaluated. Each study 
was defined as prospective or retrospective, the presence 
of a control arm was confirmed, and the randomisation 
of the treatment allocation was determined. The control 
group was assessed if assigned by the experimenter, 
or simply observed a posteriori as exposure, as in 
cohort/observational studies. Uncontrolled studies were 
excluded from meta-analytical evaluation, as studies 
failing to set up an investigational arm treated with 
fibrinogen concentrate, and a control group treated 
otherwise. In order to proceed to meta-analytical 
pooling, all outcomes were reviewed and, if observed in 
at least three of the included studies, used as a measure 
of the effect of fibrinogen concentrate in a therapeutic 
efficacy evaluation. Any relevant binary event (e.g., 
death) was comparatively pooled as risk incidence 
(e.g., overall in-hospital mortality) in a cross-sectional 
way. The protective effect of fibrinogen concentrate 
was measured as a risk ratio with Mantel-Haenszel 
weighting. Heterogeneity was reported as the I-squared 
index.
Results
Literature search
In total, 319 articles were found after the initial 
electronic and manual search (Figure 1). Of these, 264 
were excluded as focusing on other topics. Thus, 55 
potentially relevant articles were identified and the next 
screening led to the exclusion of another 48 studies (case 
reports, case series with less than ten patients included, 
reviews, protocols of randomised controlled trials, 
studies not containing informative data). The remaining 
seven studies (6 retrospective and 1 prospective)28-34 
were included in this systematic review (see Table I 
Figure 1 - Flow chart of the inclusion of the studies.
All rights reserved - For personal use only 
No other use without premission
© 
SIM
TI 
Se
rvi
zi 
Srl
320
Mengoli C et al
Blood Transfus 2017; 15: 318-24  DOI 10.2450/2017.0094-17
for the main characteristics and results of the studies 
included and the online supplementary content for 
a more detailed description). Overall, 1,650 trauma 
patients were enrolled in the seven studies evaluated28-34.
Quality assessment and outcome analysis 
The quality of evidence of the seven studies evaluated 
was poor, according to the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) 
criteria35. All studies were retrospective, except that 
by Weiss et al.31. All were cohort studies, in which 
the treatment allocation was an observed (post-hoc) 
exposure, instead of a randomised controlled trial 
or quasi-experimental studies with predetermined 
eligibility criteria and prior allocation. No study was 
randomised. Three studies were uncontrolled (Danes 
et al.28, Schoechl et al.29, Weiss et al.31), and were, 
therefore, excluded from the meta-analytic approach. 
The study by Innerhofer et al.33 was also excluded 
because all patients received fibrinogen concentrate, 
and the investigational group received fibrinogen 
concentrate plus fresh-frozen plasma (so, the topic was 
the effect of fresh-frozen plasma). All the remaining 
retrospective studies (Schoechl et al. 30, Nienaber et al.32, 
Wafaisade et al.34) depended on the German Trauma 
Register of Deutschen Gesellschaft für Unfallchirurgie 
(TR-DGU) and were evaluated for a possible meta-
analytic approach.
The outcomes were defined in several ways (Table 
II). However, overall mortality was recorded in all three 
Table I - Main characteristic of the studies included in the systematic review evaluating fibrinogen concentrate in trauma 
patients.
First 
author, 
year [ref.]
Study design N. of 
patients 
Trigger for administering 
fibrinogen concentrate
Fibrinogen 
dose
Outcomes Main results
Danes, 
2008 [28]
Retrospective 11 Fibrinogen level <1 g/L Median 4 g Mortal i ty  a t  24 
hours and 7 days 
after FC
Association between plasma 
fibrinogen levels and 7-day 
survival. No adverse effects. 
Schochl, 
2010 [29]
Retrospective 128 ROTEM MCF <10 mm Median 7 g Comparison of the 
observed 
mortality with the 
predicted mortality 
by TRISS and RISC
The observed mortality was 
24.4%, lower than the TRISS-
predicted mortality of 33.7% 
(p=0.032) and the RISC score-
predicted mortality of 28.7% 
(p>0.05).
Schochl, 
2011 [30]
Retrospective 681 
(80 FC ± PCC 
vs 601 FFP)
ROTEM MCF <10 mm Median 6 g Requirements of 
platelets and RBC 
units; mortality
RBC: 71% of patients in the 
FC group vs 97% in the FFP 
group (p<0.001). Platelets: 9% of 
patients in the FC group vs 44% 
in the FFP group (p<0.001). No 
mortality difference.
Weiss, 
2011 [31]
Prospective 
observational
62 Fibrinogen level <1.45 g/L, 
blood loss 2.0 L
4 g Hospital mortality Significant correlation between 
plasma fibrinogen level at the end 
of surgery and at 24 h post-FC; 3% 
thromboembolic complications.
Nienaber, 
2011 [32]
Retrospective 36 
(18 FC vs 
18 FFP)
ROTEM guided Median 4 g Morbidity, mortality 
and t ransfus ion 
requirements
Fewer RBC transfusions in the FC 
group (3 U vs 12.5 U, p<0.005). 
No difference in overall mortality. 
No FC-related thromboembolic 
events.
Innerhofer, 
2013 [33]
Retrospective 144 
(66 FC vs
78 FC + FFP)
ROTEM MCF <7 mm; 
fibrinogen level <1.5-2 g/L
2 g FC only;
4 g FC + FFP
C o a g u l a t i o n 
parameters before 
and after treatment; 
blood products for 
the first 24 hours; 
clinical outcomes
Fewer blood products transfused 
in the FC group (RBC: 2 U vs 7 U, 
p<0.001; platelets: 0 U vs 1 U, 
p<0.001). No difference in clinical 
outcomes.
Wafaisade, 
2013 [34]
Retrospective 588 
(294 with FC 
and 294 without 
FC)
NA NA 6-hour, 24-hour, 30-
day and in-hospital 
mortal i ty;  MOF 
incidence
6-hour mortality: 10.5% (FC+) 
vs 16.7% (p=0.03). No difference 
in 24-hour, 30-day, and in-
hospital mortality. MOF 61.2% 
in the FC vs 49% in the non-
FC group (p=0.003); 6.8% of 
thromboembolic events in FC 
vs 3.4% in the non-FC group 
(p=0.06).
ROTEM: thromboelastometry; MCF: maximum clot firmness; TRISS: Trauma Injury Severity Score; RISC: Revised Injury Severity Classification; FC: 
fibrinogen concentrate; FFP: fresh-frozen plasma; PCC: prothrombin complex concentrate; MOF: multi-organ failure; NA: not available; RBC: red blood cell.
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of these studies30,32,34, and meta-analytic pooling could be 
performed. The pooled effect of fibrinogen concentrate 
on overall mortality, measured as a risk ratio (RR) with 
Mantel-Haenszel weighting and fixed effects method, 
was not significant (RR 1.07, 95% confidence intervals 
0.83-1.38) (Figure 2). No heterogeneity was detected by 
the I-squared index (0%, p=0.604). However, the range 
of mortality rates in control groups was broad (9.9% to 
25.5%). With regards to the other outcomes of interest, 
it was not possible to perform meta-analytic pooling 
of red blood cell transfusion requirements as the three 
studies with this type of information (Schoechl et al.30, 
Nienaber et al.32, Innerhofer et al.33) were not comparable 
since Schoechl et al.30 reported data in a binary form 
(i.e., the percentage of patients who avoided red blood 
cell transfusion), Nienaber et al.32 presented their data 
in a continuous form (i.e., the median number of red 
blood cell units transfused within the first 6 and 24 
hours after admission), and Innerhofer et al.33 evaluated 
fresh-frozen plasma, and not fibrinogen concentrate, as 
their end-point. Finally, multi-organ failure was reported 
by Nienaber et al.32 and Wafaisade et al.34. Whereas the 
incidence was lower in the fibrinogen concentrate-treated 
group in the former study (16.7 vs 83.3%), the opposite 
was observed in the latter one (61.2 vs 49.0%).
Discussion
Trauma-related coagulopathy, which results from 
the rapid depletion of circulating coagulation factors 
because of consumption and blood loss, is a leading 
cause of mortality, being responsible for up to 40% of 
trauma-related deaths36,37. In cases of massive traumatic 
bleeding, the updated European guidelines recommend 
first restoration of circulating volume and secondarily 
haemostatic measures via transfusion of blood products 
or pharmaceutical agents1. In this context, the role of 
fibrinogen concentrate administered as immediate 
treatment in trauma has been investigated recently38,39. In a 
study conducted by Schochl et al.29 including 128 bleeding 
trauma patients, goal-directed coagulation management 
using thromboelastometry-guided administration of 
fibrinogen concentrate together with prothrombin 
complex concentrate was evaluated retrospectively. 
The observed mortality rate was lower in these patients 
than that predicted by the Trauma Injury Severity Score 
(TRISS) and the Revised Injury Severity Classification 
(RISC) score29. In a subsequent retrospective study 
conducted by the same group, comparing blood product 
requirements between trauma patients treated with 
fibrinogen concentrate and/or prothrombin complex 
concentrate, but no fresh-frozen plasma, and patients 
receiving only fresh-frozen plasma, it was found that 
a significantly smaller volume of blood products was 
transfused in patients receiving coagulation factor 
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Figure 2 - Effect of fibrinogen concentrate on overall in-hospital mortality.
 The effect was measured comparatively as the risk ratio (RR) in three studies amenable to meta-analytical 
pooling. Squares denote RR, with size proportional to the weight assigned to the study. Horizontal bars 
indicate 95% confidence intervals (CI) for each study. The diamond represents the aggregate effect, with 
the width representing the 95% confidence interval of the total effect. 
concentrates30. Innerhofer et al.33 compared patients who 
received fibrinogen concentrate without fresh-frozen 
plasma (n=66) or fibrinogen concentrate with fresh-
frozen plasma (n=78), reporting smaller volumes of blood 
products transfused, including red blood cells and platelets, 
in patients receiving only the fibrinogen concentrate. 
There was no difference in clinical outcomes. Propensity 
score-matching confirmed that additional fresh-frozen 
plasma administration was associated with more red 
blood cell and platelet transfusions without additional 
benefit in restoring haemostasis. A retrospective study 
of 294 trauma patients conducted by Wafaisade et al.34 
further evaluated whether administration of fibrinogen 
concentrate is associated with improved outcomes. 
Although 6-hour mortality was significantly reduced in 
the fibrinogen concentrate group, overall mortality was 
not significantly different between groups. In contrast to 
other studies, red blood cell requirement was not reduced 
in the fibrinogen concentrate group. The only published 
prospective observational study in this clinical setting 
is that by Weiss et al.31 in which a total of 223 patients 
were included, of whom 62 (28%) were trauma patients 
and received fibrinogen concentrate in association with 
fresh-frozen plasma. Interestingly, the authors found 
that plasma fibrinogen levels at the end of surgery and 
24 hours after administration of fibrinogen concentrate 
were significantly higher in the survivors than in the 
non-survivors. 
The current evidence on the use of fibrinogen 
concentrate in massive bleeding associated with severe 
trauma is mostly restricted to retrospective analyses. 
Indeed, of the seven studies identified in this systematic 
review (Table I), only one was prospective. In addition, 
although a wide array of outcomes were assessed by 
the different studies, rendering a comparative analysis 
very difficult, we were able to perform a meta-analysis 
of three retrospective studies that evaluated the main 
outcome, overall mortality. 
In general, although a number of studies have 
reported on the use of fibrinogen concentrate for the 
treatment and prevention of acquired bleeding, its 
beneficial effect is still debated, mainly because of the 
low quality of the published clinical evidence and the 
data collected seem weak and insufficient as a basis for 
therapeutic or prophylactic guidelines40.
The results of our meta-analysis do not support a 
benefit in terms of survival from the use of fibrinogen 
concentrate in the setting of severe trauma. We are, 
however, aware of the methodological flaws of this 
research, mainly due to the limited amount and poor 
quality of the data retrieved41. Nevertheless, this is the 
first attempt to perform meta-analytic pooling of studies 
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focused on the use of fibrinogen concentrate in traumatic 
haemorrhage. The final results of ongoing randomised 
controlled trials are required to overcome the biases 
present in the current literature and fully elucidate the 
effects of fibrinogen concentrate on allogeneic blood 
transfusion requirements and on survival in severely 
injured patients. We would like to highlight, however, 
that the early use of the relatively inexpensive and 
widely available haemostatic agent, tranexamic acid, 
has already shown a survival benefit in this clinical 
context in the frame of the Clinical Randomization 
of an Antifibrinolytic in Significant Haemorrhage-2 
(CRASH-2) trial42,43.
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